Sleep quality and other patient-reported outcomes improve after psoriasis patients with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial
British Journal of Dermatology, 08/17/2012
Clinical Article
Strober BE et al. – Adalimumab treatment improved sleep outcomes and other patient–reported outcomes including health–related quality of life, work productivity, daily activity, and disease–related pain.



